olverembatinib
ascentage pharmaceuticals
['olverembatinib']
dcbn news: asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3%: suzhou, china, and rockville, md., june ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.